Notice of Half-Year Report

RNS Number : 2633X

Faron Pharmaceuticals Oy

27 August 2020

 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Notice of Half-Year Report

Company announcement, 27 August 2020 at 9.00 AM (EET)

TURKU - FINLAND, 27 August 2020 - Faron Pharmaceuticals Ltd ( " Faron") (LON: FARN), the clinical stage biopharmaceutical company , will announce its unaudited half-year report for the six months ended 30 June 2020 on Thursday 24 September 2020.

Dr. Markku Jalkanen, Chief Executive Officer, Toni Hänninen, Chief Financial Officer, and Yrjö Wichmann, VP Financing will host a conference call and webcast followed by a Q&A session at 12:30 pm BST (7:30 am EST) to discuss the financial results and operating results .   Please contact Consilium Strategic Communications for further details.

ENDS

For more information please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

[e-mail]  

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Tony Rawlinson, Mark Rogers

Phone. [phone] 

Panmure Gordon (UK) Limited, Broker

Rupert Dearden

Phone: [phone] 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen, Jussi Majamaa

Phone: [phone]

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: [phone]

E-mail: [e-mail]

Stern Investor Relations, Inc.

Julie Seidel, Naina Zaman

Phone: +(1)212 362 1200

Email: [e-mail]  

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine. Faron is based in Turku, Finland. Further information is available at www.faron.com  

 

END

 

 

NORKKABNKBKBQFB